Hyperion Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
November 26, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 25th Annual Piper Jaffray Healthcare...
Hyperion Therapeutics to Present at the Jefferies 2013 London Healthcare Conference
November 15, 2013 09:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Jefferies 2013 London Healthcare...
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results
November 12, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $15.5 million during the third quarter of 2013 which includes...
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results Teleconference and Webcast
November 06, 2013 09:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a teleconference and webcast with management to provide a...
Hyperion Therapeutics Announces Initiation of THRIVE Study, a Long-Term Registry of Patients With Urea Cycle Disorders
October 31, 2013 09:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has begun enrolling patients in its THRIVE study, a long term registry...
Sobi Gains Rights to Distribute RAVICTI(R) on a Named Patient Use Basis in Middle East From Hyperion Therapeutics, Inc.
October 01, 2013 07:00 ET
|
Hyperion Therapeutics, Inc.
STOCKHOLM, Sweden and SOUTH SAN FRANCISCO, Calif., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) and Hyperion Therapeutics, Inc., (Nasdaq:HPTX) announced today...
Hyperion Therapeutics to Present at the Leerink Swann Rare Disease Day
September 26, 2013 09:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Leerink Swann Rare Disease Day on...
Hyperion Therapeutics to Present at the Annual Stifel 2013 Healthcare Conference
September 05, 2013 16:30 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the annual Stifel 2013 Healthcare...
Hyperion Therapeutics Announces Presentation of Long Term Data on Ammonia Control in Pediatric Patients Treated With RAVICTI(R) at the 12th International Congress of Inborn Errors of Metabolism and the Urea Cycle Disorder Satellite Symposium
September 03, 2013 08:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced several data presentations at the 12th International Congress of Inborn Errors...
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results
August 14, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $7.3 million following the first full quarter of sales of its...